NCT06082804Recruiting
Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
Chronic Myeloid Leukemia (CML) affects 820 people per year in France (2018), half of them are older than 60 years old. Tyrosine Kinase Inhibitors (TKI) are new kind of targeted therapy whose efficiency allow for a high rate of complete molecular response, leading to a disruption of treatment under certain conditions. Optimizing CML treatment is a major concern, particularly for adverse events management, treatment compliance and therapeutic response. Multiple studies demonstrated that grade ≤ II adverse events are most likely to be under reported by patients and clinicians. Although these adverse events are mostly reported by clinical examination, needing minimal treatment. These toxicities could alter daily and domestic living activities, potentially impacting treatment compliance and therapeutic response. Therefore, early detection of these adverse events is a major challenge for the prognosis and care of CML. The Advanced Practice Nurse (APN), a new health care professional, acquired the skills needed to independently follow, manage and care the patients with medical approvals. At international level, many studies, in oncology and in others domains, have been done to demonstrate the added value of the APN, particularly in improving patient's quality of life, management, care of drug-induced adverse events and treatment compliance. In France, because of the recentness of the profession, only few studies were have been conducted. The goal of this study is to demonstrate the benefit of APN in clinical follow-up, quality of life, treatment compliance, and therapeutic response of CML patients. These effects could be managed thanks to early detection and management of ≤ grade II adverse events during consultation, in partnership with the patients, and in collaborative working.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 9 Oct 2023
- Start date
- 29 Nov 2023
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Centre Hospitalier Henri Duffaut - Avignon
- Diseases
- Chronic myeloid leukaemia
- NCT number
- NCT06082804
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 29 Nov 2023 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient that had a follow-up \> 3 months by an advanced practice nurse for CML before inclusion.
- Patient changing treatment for toxicities, if these toxicities are still \> grade I at inclusion.
- Patient enrolled in another interventional research protocol for CML.
- Pregnant women.
- Patient under legal protection, deprived of liberty or unable to be included in a research protocol.
Who the study is looking for
- Age ≥ 18 years old.
- CML patient in chronic phase, eligible for oral therapy.
- Newly diagnosed CML and/or initiating oral therapy :
- Patient changing treatment for non-response or loss of therapeutic response or toxicities, on the condition that these toxicities are resolved or grade I maximum at the time of inclusion.
- Newly start of oral therapy.
- Patient eligible to a follow-up by an advanced practice nurse.
- Patient capable to understand french and complete a questionnaire.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier d'Avignon, Hôpital Henri Duffaut Coordinator of this site? Confirm its status | Avignon | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.